AUS
NZ
UK
CA
USA
IND
Healthcare
Is Myriad Genetics Poised for Growth?
October 11, 2024 02:46 PM PDT| By Team Kalkine MediaHighlights,Multiple insider transactions, including significant transactions, have been observed at Myriad Genetics, Inc. over the past year, drawing attention from shareholders.,Insider selling can carry different meanings, but when key executives,...
Cardiol Therapeutics is advancing clinical trials of its pure cannabidiol product, CardiolRx, for inflammatory heart disease treatment
October 11, 2024 12:56 PM PDT| By Team Kalkine MediaHighlights,Cardiol Therapeutics Inc. is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with a lead candidate in clinical trials.,The company has successfully raised $15.5 million through a public offering to ad...
Aetna Celebrates 88% of Medicare Advantage Members in 4-Star or Higher Plans for 2025
October 11, 2024 02:05 AM PDT| By Team Kalkine MediaHighlights,Aetna, a CVS Health company, reports that 88% of its Medicare Advantage members are enrolled in plans rated 4 stars or higher for 2025, with 68% in 4.5-star plans.,The company achieved its highest-ever member experience score since the inc...
Clover Health's PPO Medicare Advantage Plans Achieve High Rating for 2025
October 11, 2024 01:59 AM PDT| By Team Kalkine MediaHighlights,Clover Health’s PPO Medicare Advantage plans have received a Star rating increase to 4 Stars for 2025, impacting payment year 2026.,The HMO Medicare Advantage plan rating has also risen to 3.5 Stars, with over 95% of Clover’s Medicare Adva...
Is Pfizer's Dividend a Sign of Strength?
October 10, 2024 03:26 PM PDT| By Team Kalkine MediaHighlights:,Pfizer’s long-standing commitment to shareholder value is reaffirmed with its 344th consecutive quarterly dividend, underlining the company's consistency in returning profits to shareholders.,The announcement demonstrates the company's fi...
Tempest Enters Agreement with Roche to Progress Amezalpat Therapy in Hepatocellular Carcinoma
October 10, 2024 05:33 AM PDT| By Team Kalkine MediaHighlights:,Tempest Therapeutics has entered into an agreement with Roche to advance amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab into a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepato...
Brokers Acknowledge GSK's Zantac Settlement as a 'Positive Development'
October 10, 2024 05:22 AM PDT| By Team Kalkine MediaHighlights:,GSK PLC has reached a $2.2 billion settlement that addresses 93% of the ongoing litigation related to its heartburn medication Zantac, which is viewed as a favorable outcome by analysts.,The settlement includes a $70 million payment to Va...
GSK Confirms $2.2 Billion Settlement for US Zantac Lawsuit
October 10, 2024 04:05 AM PDT| By Team Kalkine MediaHighlights:,GSK PLC has reached a settlement agreement of up to $2.2 billion to resolve approximately 80,000 lawsuits related to its heartburn medication Zantac.,The settlement will address 93% of state court cases, with completion anticipated by mid...
Cardiol Therapeutics has confirmed the pricing of its public offering at $13.5 million
October 09, 2024 06:20 AM PDT| By Team Kalkine MediaHighlights:,Cardiol Therapeutics is raising US$13.5 million through a public offering of 8,437,500 Class A common shares at a price of $1.60 per share.,Proceeds from the offering will primarily be directed towards advancing the clinical development o...
Clearside Biomedical has shared positive topline findings from its ODYSSEY Phase 2b trial of Suprachoroidal CLS-AX in wet AMD
October 09, 2024 05:30 AM PDT| By Team Kalkine MediaHighlights:,The ODYSSEY Phase 2b trial of CLS-AX demonstrated stable visual acuity and anatomical control over nine months.,The trial showed a positive safety profile with no ocular or treatment-related serious adverse events reported.,A significant...
Haleon has benefited from an increase in sales estimates following UBS's revision of its long-term outlook
October 09, 2024 05:03 AM PDT| By Team Kalkine MediaHighlights:,Haleon PLC has been upgraded by UBS, with an increased price target of 445p, reflecting confidence in the company’s long-term revenue prospects.,Despite a 3% reduction in adjusted earnings due to foreign exchange fluctuations, UBS remains...
Myriad Genetics, Inc. (NASDAQ: MYGN) Enhances Breast Cancer Research with Molecular Residual Disease Testing
October 09, 2024 02:12 AM PDT| By Team Kalkine MediaHighlights,Myriad Genetics announces significant research collaborations to improve breast cancer treatment.,Studies will utilize the Precise® MRD test to explore circulating tumor DNA (ctDNA) in various breast cancer scenarios.,The focus is on enhan...
Tonix Pharmaceuticals Develops Innovative Fibromyalgia Treatment
October 08, 2024 02:38 PM PDT| By Team Kalkine MediaHighlights,Tonix Pharmaceuticals' innovative drug formulation aims to improve fibromyalgia treatment by enhancing drug absorption and stability.,Ongoing unmet needs for fibromyalgia treatments continue to drive research and development in the sector....
IQVIA's Price Target Adjustments Indicate Analyst Confidence
October 08, 2024 12:38 PM PDT| By Team Kalkine MediaHeadlines,Price Target Adjustment for IQVIA,Analyst Ratings Reflect Positive Sentiment,Future Outlook for IQVIA Stock,IQVIA,(NYSE:IQV),has recently experienced a price target adjustment from analysts at Evercore ISI, which lowered the target from 270...
Pfizer’s Stock Performance: Analyst Insights and Future Outlook
October 08, 2024 12:36 PM PDT| By Team Kalkine MediaHeadlines,Pfizer experiences a slight increase in trading activity, with notable analyst upgrades.,The stock remains a subject of varied ratings from several research firms.,Analysts project a positive outlook for Pfizer's price movement based on rec...
Novo Nordisk: Positive Analyst Ratings Persist Amid Slight Price Adjustment
October 08, 2024 12:31 PM PDT| By Team Kalkine MediaHeadlines,Novo Nordisk experiences a slight decline in share price,Analysts provide updated target prices reflecting positive outlook,Consensus remains favorable despite minor trading fluctuations,Novo Nordisk,(NYSE:NVO),A/S shares traded down during...
Vivos' OSA Devices Receive AMA Support for Coverage
October 08, 2024 12:12 PM PDT| By Team Kalkine MediaHighlights,The American Medical Association's approval of new CPT codes for Vivos' devices marks a major milestone. These codes, effective next year, will facilitate streamlined insurance coverage and reimbursement for the company's FDA-cleared oral...
KindlyMD Partners with UnitedHealthcare to Expand Patient Access
October 08, 2024 07:39 AM PDT| By Team Kalkine MediaHighlights:,KindlyMD’s new contract with UnitedHealthcare will begin on November 1, 2024, enhancing patient access.,The partnership aims to reduce out-of-pocket costs for patients, promoting holistic healthcare solutions.,KindlyMD’s commitment to inn...
Precipio, Inc. Launches Enhanced Bloodhound MPN Panel to Revolutionize CALR Mutation Analysis
October 08, 2024 07:28 AM PDT| By Team Kalkine MediaHighlights,- New capabilities distinguish between CALR type 1 and type 2 mutations.,- Alignment with the latest NCCN guidelines enhances clinical decision-making.,- First quantitative PCR-based panel offering detailed CALR subtyping in MPN diagnostic...
Accolade has confirmed its results for the fiscal second quarter of 2025
October 08, 2024 06:02 AM PDT| By Team Kalkine MediaHighlights:,Accolade reported a 10% increase in revenue for fiscal Q2 2025, reaching $106.4 million, with a notable 27% improvement in net loss to $23.9 million.,Non-GAAP Adjusted EBITDA loss narrowed significantly by 68% to $2.8 million, while Adjus...
